Objective: Carotid endarterectomy (CEA) has been shown to be an effective treatment for patients with asymptomatic carotid artery stenosis when perioperative stroke rates are low and patients survive long enough to benefit from the intervention. Our objective was to develop and to validate a simple risk prediction model for 30-day stroke and 1-year mortality to guide optimal selection of patients for CEA.
Carotid endarterectomy (CEA) has been shown to reduce the risk of stroke or death in patients with severe carotid stenosis, and this benefit is most pronounced in patients with symptomatic disease. Both the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST) demonstrated a 3.8% to 8.3% per year reduction in any stroke or death with carotid surgery over medical treatment. 1, 2 The companion major randomized trials for asymptomatic disease also demonstrated a benefit of surgery with medical treatment over medical treatment alone, but the benefit was much smaller. The Asymptomatic Carotid Surgery Trial (ACST) and the Asymptomatic Carotid Atherosclerosis Study (ACAS) both demonstrated a reduction in stroke or death of approximately 1% per year. 3, 4 Current guidelines from the Society for Vascular Surgery recommend consideration of CEA for patients with asymptomatic carotid artery stenosis of >60% with a life expectancy of 3 to 5 years and a procedural stroke or death rate of <3%. 5 This is similar to European guidelines and the American Heart Association/American College of Cardiology guidelines in that treatment of patients with severe asymptomatic carotid stenosis must incorporate life expectancy, comorbid factors, and the proceduralist's outcomes. 6, 7 Currently, there are limited methods to assess patients for survival after CEA. Although risk prediction models for perioperative stroke are available, 8, 9 validated models for bedside application to assist in selection of patients are limited. 10 The purpose of this study was to use the Vascular Quality Initiative (VQI), a nationwide quality registry including patients undergoing CEA, both to develop and to validate a model to predict perioperative stroke and 1-year mortality using preoperative patient factors. This would allow providers to inform patients of their anticipated stroke risk and to select patients likely to live long enough to realize the benefit from prophylactic endarterectomy.
METHODS
Database. This is a retrospective review of asymptomatic patients undergoing CEA for extracranial internal carotid artery occlusive disease within the VQI. The VQI is a nationwide quality improvement initiative to improve outcomes of vascular procedures. 11 Registry data are compared with hospital claims in annual audits and missing cases are retrieved to track all procedures. 12 Mortality data are assessed at 1-year follow-up and also supplemented by monthly matching of registry data with the Social Security Death Index. Physicians, nurses, or clinical data abstractors entered data prospectively on clinical and demographic variables. Research analysts were blinded to patient, surgeon, and hospital identity. The Institutional Review Board at Mayo Clinic has approved the use of deidentified data from the VQI for research purposes. Consent of the patients was not obtained or deemed necessary by the Mayo Clinic Institutional Review Board. The VQI is an Agency for Healthcare Research and Qualitylisted Patient Safety Organization authorized under the Patient Safety and Quality Improvement Act of 2005 to allow collection of patient data without consent for quality improvement purposes.
Analytic cohort. All patients undergoing CEA from 2010 to 2015 were identified within the VQI from 265 centers. Patients were excluded for any prior ipsilateral cortical or ocular neurologic symptoms. We also excluded patients with any prior vertebrobasilar neurologic events and those with urgent or emergent admission. This was to ensure that we created a cohort of patients with purely asymptomatic disease. For patients with multiple procedures, only the first procedure in the registry was used for analysis.
Definitions and outcomes and exposure variables. Our outcomes were any 30-day stroke and 1-year mortality. Stroke within 30 days was defined as any (ipsilateral or contralateral) neurologic symptoms lasting 24 hours or longer, including motor or sensory loss, speech abnormality, visual loss, and other neurologic symptoms documented in the medical record in the postoperative period by examination. Postoperative physician neurologic assessments (by the primary team or by the neurology service) and imaging are not standardized across the VQI. However, data are reported in an anonymous fashion, so there is no incentive to underreport postoperative events. Postoperative transient ischemic events (lasting <24 hours) were not included in our outcome of stroke. The date of postdischarge stroke is assessed at 1-year follow-up, which enables calculation of 30-day stroke rates. One-year mortality was assessed by two mechanisms. Mortality status is recorded at 1-year follow-up and supplemented by monthly integration of Social Security Death Index events.
Characteristics of the patients that are available preoperatively were assessed as potential factors that could predict 30-day stroke and 1-year mortality. Factors assessed included age, race, ethnicity, sex, body mass index, ambulatory status, prior peripheral vascular history, and preoperative medication use (aspirin, P2Y 12 antagonists, statins, and beta blockers 13 ). In addition, comorbidities of hypertension, smoking status, diabetes, coronary disease, pulmonary disease, and renal disease (by estimated glomerular filtration rate [eGFR] calculations 14 ) were assessed. Patients were assessed for severity of carotid stenosis by ultrasound (with severity of stenosis assigned by local criteria at each institution), computed tomography angiography, magnetic resonance imaging, or conventional angiography. In addition, the surgeon's annual volume and average procedural time were assessed as potential predictors of each outcome. Statistical analysis. An analytic data set was created for each outcome. For the outcome of stroke, 27 patients with missing data on postoperative stroke were excluded. This resulted in a final cohort of 31,939 patients for the 30-day stroke analysis. For 1-year mortality, we used patients from 2010 to 2014 only to allow full 1-year follow-up of all patients. An additional 126 patients were excluded for missing data on 1-year mortality (all cases were in December 2014), leaving 23,512 patients. The mortality data set was then divided into a derivation set (n ¼ 18,629) and validation set (n ¼ 4883). The stroke data set was not divided because of the low number of events.
ARTICLE HIGHLIGHTS
Once the analytic cohort for stroke and the derivation cohort for mortality were created, missingness of exposure variables was assessed and missing data were imputed as detailed by Harrell. 15 Missingness for all candidate predictors was <15%. Mean/mode imputation was done for variables with <5% missingness, and "best guess" regression-based imputation was done for variables with 5% to 15% missingness. For each outcome, univariate comparisons were made for the candidate exposure variables using t-tests for continuous variables and c
or Fisher exact test for categorical variables.
A single analysis of the data set may not represent future data sets because of some random occurrence of events. Thus, to ensure that the selection of variables would be associated with both stroke and mortality in future data sets, a backward stepwise elimination algorithm was bootstrapped 100 times and the predictors were ranked according to the number of times they were selected for the final model. 16 This technique involves resampling the data set 100 times and defining predictors of stroke or death, simulating 100 different data sets. This allows greater precision on estimates and reduces the effect of random events on a single data set. With this, we selected the variables that would maximize the ability to predict stroke or death (as defined by the area under the receiver operating characteristic curve [AUC]) for our risk prediction model. We selected factors from >40 potential factors for each model (final model has 11 factors for stroke and 10 factors for mortality). This provided 97% and 98% of the total AUC for the stroke and mortality models, respectively. Thus, by using these factors, our model is nearly identical to a model with 40 factors and is greatly simplified. We then investigated all possible two-way interactions among the chosen predictors, applying a Bonferroni threshold for significance of P < .001. No interactions significantly improved model fit.
Validation. For the outcome of stroke, we performed two methods of internal validation. First we used bootstrapping as described by Efron. Penalized maximum likelihood estimation was used to correct the model coefficients for overfitting using the "pentrace()" function in the R package "rms."
15 After penalization, we internally validated the model by following the method of Efron.
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We performed bootstrapping (1000 iterations) to estimate the bias due to overfitting or "optimism" in the AUC and the calibration intercept and slope of the model. We subtracted the optimism from the original estimates to arrive at "bias-corrected" estimates of the discrimination and calibration that we would expect to observe in a new data set. Second, we performed two iterations of a 10-fold crossvalidation. We randomly divided the data into 10 equal parts. One part was held out as a test set, and we repeated all of the model-building steps performed before using the remaining nine parts as the training set. We then used the resulting model to predict stroke in the test set and recorded the AUC and the calibration intercept and slope. We repeated this process 9 more times to complete a single iteration of the 10-fold process. We took the median of the results across both iterations as estimates of the expected AUC and calibration parameters on a new data set.
For the outcome of 1-year mortality, we performed internal bootstrapping validation (as described before for our stroke outcome). In addition, we used our split sample for validation. The coefficients from the derivation set were applied to the validation set to estimate the probability of death within 1 year for each patient in the validation data set. The multivariable model coefficients for 30-day stroke and 1-year mortality were normalized to the lowest coefficient to create risk score to estimate stroke or death. Because of the number of factors in each model, this risk score would span 0 to 500 and would be cumbersome to calculate. Therefore, the models were made available on QxMD.com (http:// qxmd.com/calculate/calculator_389/vascular-qualityinitiative-vqi-30-day-stroke-risk-index-for-cea and http:// qxmd.com/calculate/calculator_390/vascular-qualityinitiative-vqi-1-year-mortality-risk-index-for-cea) for easier point of care use without the need for calculation of the risk score. However, for publication, we also created estimated risk terciles for each outcome using these coefficients. This was to assist in rapid estimation of risk category without the need for calculations to easily estimate stroke and mortality risk. All analyses were performed using the R statistical software package (V. 3.2.4; R Foundation for Statistical Computing, Vienna, Austria). P values of < .05 were considered significant, apart from the interaction tests, which were done with a Bonferroni correction.
RESULTS
Thirty-day stroke. There were a total of 31,939 patients for 30-day stroke analysis. The mean stroke rate across the 265 VQI centers was 0.9%. Excluding one center that treated a single patient who experienced the event, stroke rates by center varied from 0% to 8.3%. Eighty-five One-year mortality. For our end point of 1-year mortality, we identified 23,512 patients for analysis. Of these, 18,629 were used as a derivation group for model development and 4883 were used for a validation subset. The mean 1-year mortality in the VQI was 3.4% and varied from 0% to 20% across VQI centers. Of all centers, 22% had a 1-year mortality rate above 5%. Factors associated with 1-year mortality are outlined in Table III. Based on our bootstrapping selection algorithm, 10 factors were selected for our 1-year mortality model (Supplementary Table III, online only; Table IV) . Our model had an AUC of 0.76. This was within 96% of the full AUC if all factors were included. Factors associated with higher odds of 1-year mortality were anemia, ASA class, age, smoking status, contralateral carotid occlusive disease in addition to severity of renal disease, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and diabetes. A normal result of the stress test (when performed) was associated with lower odds of 1-year mortality (Table IV) .
With bootstrapping internal validation, we obtained a bias-corrected AUC of 0.750 with a bias-corrected calibration plot intercept and slope of 0.035 and 1.01, respectively. Second, using our derivation model, its coefficients were used to estimate the probability of death within 1 year for each patient in the validation data set 
DISCUSSION
Using the VQI CEA registry, we have been able both to develop and to validate risk prediction models for 30-day stroke and 1-year survival after CEA in asymptomatic patients. Currently, most centers perform CEA with a 30-day stroke rate below 2%, yet rates are higher in a subset of centers. Patients at higher risk for stroke include female patients and those with more severe comorbid conditions, prior vascular history, less severe ipsilateral stenosis, and more severe contralateral disease, whereas the use of aspirin and P2Y 12a antagonists led to lower stroke rates. Similarly, overall 1-year mortality was low; however, nearly a quarter of centers had 1-year mortality rates exceeding 5%. This is higher than the anticipated stroke risk reduction for the first several years after surgery, suggesting that selection of patients could be improved in these centers. Factors we validated for 1-year survival included age and more severe comorbidity burdens, higher body mass index, current and prior smoking, abnormal result of stress testing, anemia, prior vascular surgery, and contralateral disease. Normal stress test results were associated with lower 1-year mortality.
The efficacy of carotid intervention for stroke reduction in the setting of severe carotid stenosis has been well established since the publication of both the ACAS and ACST 3, 4 that demonstrated an absolute risk reduction of 5.9% and 5.4%, respectively, for any stroke or death within 5 years of randomization. However, the risk of stroke with medical treatment is likely to have improved since these trials started. Naylor suggested that there has been as much as a 70% reduction in the 5-year risk of ipsilateral stroke since 1995, which is now <1% per year with medical management. 18 With improvements in medical therapy and declining stroke rates, selection of patients for intervention in asymptomatic carotid stenosis is even more critical to ensure that patients are likely to receive a benefit from prophylactic intervention. Few studies have attempted to study only asymptomatic patients to assist in defining at-risk patients for both stroke and survival. Our findings are unique in that they are the first to be validated to predict both stroke and survival after CEA for asymptomatic carotid artery stenosis. Our data demonstrated that declining eGFR and increasing severity of COPD, CHF, diabetes, ASA class, contralateral carotid stenosis, and current and prior smoking status are associated with reduced 1-year survival. These factors are similar to but more extensive than those identified in other studies and can be used to estimate 1-year mortality risk (Table V) . In a single-center series, Conrad et al developed a risk prediction model for 5-year survival for asymptomatic patients treated from 1989 to 2005. They also found that increasing age, COPD, CAD, diabetes, prior neck irradiation, lack of statin use, and a creatinine concentration >1.5 mg/dL were associated with reduced 5-year survival. 19 Similarly, a study of >6100 patients in the Swedish Vascular Registry identified advanced age, prior vascular surgery, and diabetes as risk factors for reduced long-term survival. 20 In two different studies from Dartmouth using the Vascular Study Group of New England 21 and the Vascular Quality Initative, 22 researchers identified patient factors and severity of comorbid diseases similar to our findings. However, our paper uniquely identified preoperative anemia as one of the factors most strongly associated with 1-year mortality (odds ratio of 2.6 for preoperative hemoglobin level <10 mg/dL). Baseline anemia can be a marker of chronic disease, and it may be a strong predictor of midterm mortality and may be useful in future risk models. In addition, our series included data up to 2015. The VQI has grown substantially from 100 centers in 2011, used in the studies by the Dartmouth group, to nearly 350 centers in 2015. This increases the generalizability of our findings.
We also derived and validated a risk prediction model for 30-day stroke after CEA for asymptomatic patients. This is unique as most prior reports include both symptomatic and asymptomatic patients; use the combined end points of stroke, myocardial infarction, and death; or are single-center series. We used a nationwide vascular surgery registry of only asymptomatic patients to identify several detailed factors associated with 30-day stroke. In a similar study, Calvillo-King et al used the New York Carotid Artery Surgery Registry with enriched claims data to define eight factors associated with 30-day stroke that they validated. Similar to our findings, they identified women, contralateral stenosis, and CAD as groups at higher risk for 30-day stroke. 10 They also identified CHF, distant transient ischemic attack or stroke, nonwhite race, and severe disability as additional factors. Using the National Surgical Quality Improvement Program database, Woo et al identified COPD, CHF, and prior myocardial infarction as risk factors for stroke or death within 30 days. 9 Finally, our results expand on the data from the Vascular Study Group of Northern New England, which showed that only age >70 years and a contralateral occlusion were predictive of stroke or death in 30 days. 8 Our results add granularity to the risk factors for stroke after CEA. Because of the number of patients and events, we were able to demonstrate the association of increasing severity of CAD, renal disease, and contralateral stenosis with the risk of stroke beyond what has been previously demonstrated. We also identified anemia as a stroke risk factor, and we demonstrated the protective association of antiplatelet agents (aspirin and P2Y 12 antagonists) with the risk of stroke. These factors were not identified in prior studies. A simplified risk score based on our model can be used to estimate the 30-day stroke risk (Table VI) . Interestingly, we identified a lower stroke rate with more severe ipsilateral stenosis compared with the #60% stenosis group.
Patients treated with #60% stenosis were a small subset of the patients (2.9%) but had a significantly higher rate of stroke (1.7%). The indication for CEA in those with #60% stenosis in this series is unclear, but these patients were likely to be at higher risk for an unknown cause, such as unstable or progressive plaque, ulcer, or other feature that we cannot adjust for. This finding will need further study to determine whether this is unique to this data set and patient group. This study has several inherent limitations. We can demonstrate only associations and not causation of patient factors with stroke or 1-year survival. In addition, the VQI CEA registry contains only patients selected for CEA. We do not know how many patients were not offered CEA by the same surgeons to fully understand selection of patients. The planned Vascular Medicine Registry of the VQI will track patients with carotid stenosis who are treated without intervention and managed medically. We also recognize that our model for stroke has limited discriminatory ability with an AUC of 0.67. However, this is similar to other risk prediction models for stroke. 8, 10 This finding underscores the difficulty in developing stroke prediction models despite the numerous data available in the VQI on patient, procedural, surgeon, and center details.
CONCLUSIONS
Proper selection of patients for CEA is critical to ensure that patients face a minimal stroke risk and will survive long enough to benefit from intervention. With evidence to suggest declining stroke rates with rigorous medical management, the therapeutic benefit of intervention will be entirely based on how well patients are selected. Using a national vascular quality improvement database, we have both derived and validated risk models for 30-day stroke and 1-year mortality. These models will be useful in web-based applications (QxMD.com), so point of care data are available to patient and providers about the anticipated risks of surgery. To ensure appropriateness of care, patients with a 1-year mortality risk exceeding 2% may be best served with medical therapy.
Incorporation of data from medically managed patients in the future VQI Vascular Medicine Registry will be vital to further enhance these models. These data can improve education of the patient and understanding of their risks to make choices based on their preferences. 
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